Kristine Alison Pozatek, LICSW | |
1305 Vt Route 14 N, E Montpelier, VT 05651-4415 | |
(802) 522-2241 | |
Not Available |
Full Name | Kristine Alison Pozatek |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 1305 Vt Route 14 N, E Montpelier, Vermont |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518068139 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 089-0001098 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kristine Alison Pozatek, LICSW 1305 Vt Route 14 N, E Montpelier, VT 05651-4415 Ph: (802) 522-2241 | Kristine Alison Pozatek, LICSW 1305 Vt Route 14 N, E Montpelier, VT 05651-4415 Ph: (802) 522-2241 |
News Archive
Researchers at RAND found the result of offering rebates for healthy foods can lead to shifts in diets, which could have public policy implications.
PharmaDerm, a division of Nycomed US Inc., announced today that VEREGEN (sinecatechins) Ointment, 15%, a topical medication for the treatment of external genital and perianal warts, has been added as a new therapeutic option in the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.
Olivier De Schutter, the U.N. special rapporteur on the right to food, writes in a Guardian opinion piece, "In order to support investment in agriculture, governments have ... come to rely on private sector investment and development aid - and increasingly a partnership of the two," and he notes "the New Alliance for Food Security and Nutrition, proposed by U.S. President Barack Obama and the U.S. Agency for International Development and launched in May 2012, will draw more than $3 billion of private sector investment into food security plans in Africa."
Twelve percent of adults in Sweden have diseases related to their use of medicines. But in four cases of ten it would have been possible to avoid the undesired effects.
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that patients treated with ISIS-CRPRx achieved rapid, dose-dependent mean reductions of up to 67 percent in C-reactive protein (CRP) in a Phase 2 study in patients with rheumatoid arthritis (RA).
› Verified 1 days ago